344823 165ho r d systems (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
344823 165ho r d systems
344823 165ho R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 145 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mab2365/Human+TIM-3+Antibody/pm39137729-228-12-14
Average 94 stars, based on 145 article reviews
344823 165ho R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 145 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mab2365/Human+TIM-3+Antibody/pm39137729-228-12-14
Average 94 stars, based on 145 article reviews
344823 165ho r d systems - by Bioz Stars,
2026-10
94/100 stars
Images
Related Articles
Control:Article Title: T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction Article Snippet: The anti-CEACAM5/6 antibody h16 C3 (as described in US20130189268,34 human IgG1,35,36), the antihuman CEACAM1 antibody (as described in WO2013054320,37 human IgG1 (TPP-3006) and human IgG2 (TPP-9145)) and isotype control antibodies TPP-1238 (huIgG2), TPP-1240 (huIgG4-S228P), and TPP-754 (huIgG1) were generated at Bayer AG. .. Article Title: T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction Article Snippet: The anti-CEACAM5/6 antibody h16 C3 (as described in US20130189268, human IgG1, , ), the anti-human CEACAM1 antibody (as described in WO2013054320, human IgG1 (TPP-3006) and human IgG2 (TPP-9145)) and isotype control antibodies TPP-1238 (huIgG2), TPP-1240 (huIgG4-S228P), and TPP-754 (huIgG1) were generated at Bayer AG. .. Recombinant:Article Title: T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction Article Snippet: The anti-CEACAM5/6 antibody h16 C3 (as described in US20130189268,34 human IgG1,35,36), the antihuman CEACAM1 antibody (as described in WO2013054320,37 human IgG1 (TPP-3006) and human IgG2 (TPP-9145)) and isotype control antibodies TPP-1238 (huIgG2), TPP-1240 (huIgG4-S228P), and TPP-754 (huIgG1) were generated at Bayer AG. .. Article Title: T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction Article Snippet: The anti-CEACAM5/6 antibody h16 C3 (as described in US20130189268, human IgG1, , ), the anti-human CEACAM1 antibody (as described in WO2013054320, human IgG1 (TPP-3006) and human IgG2 (TPP-9145)) and isotype control antibodies TPP-1238 (huIgG2), TPP-1240 (huIgG4-S228P), and TPP-754 (huIgG1) were generated at Bayer AG. .. Article Title: Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Article Snippet: In brief Glioblastoma (GBM) represents an aggressive brain malignancy with limited treatments.. Shanley et al. engineer NK cells to express interleukin (IL)-21, which show superior safety and long-term antitumor activity compared to IL-15 NK cells.. Key transcription factors like CEBPD drive this enhanced function, suggesting that IL-21 reprograms NK cells epigenetically, enhancing their therapeutic efficacy against GBM. Purification:Article Title: Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Article Snippet: In brief Glioblastoma (GBM) represents an aggressive brain malignancy with limited treatments.. Shanley et al. engineer NK cells to express interleukin (IL)-21, which show superior safety and long-term antitumor activity compared to IL-15 NK cells.. Key transcription factors like CEBPD drive this enhanced function, suggesting that IL-21 reprograms NK cells epigenetically, enhancing their therapeutic efficacy against GBM. Multiple Displacement Amplification:Article Title: Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Article Snippet: In brief Glioblastoma (GBM) represents an aggressive brain malignancy with limited treatments.. Shanley et al. engineer NK cells to express interleukin (IL)-21, which show superior safety and long-term antitumor activity compared to IL-15 NK cells.. Key transcription factors like CEBPD drive this enhanced function, suggesting that IL-21 reprograms NK cells epigenetically, enhancing their therapeutic efficacy against GBM. Enzyme-linked Immunosorbent Assay:Article Title: Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Article Snippet: In brief Glioblastoma (GBM) represents an aggressive brain malignancy with limited treatments.. Shanley et al. engineer NK cells to express interleukin (IL)-21, which show superior safety and long-term antitumor activity compared to IL-15 NK cells.. Key transcription factors like CEBPD drive this enhanced function, suggesting that IL-21 reprograms NK cells epigenetically, enhancing their therapeutic efficacy against GBM. |